| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Kaplan SA | |
| Newman DK | |||
| Ohl DA | |||
| Staskin DR | |||
| Rosenberg MT | |||
| MacDiarmid SA | |||
| P2860 | cites work | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. | Q42539019 |
| A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | Q46577111 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1535-1546 | |
| P577 | publication date | 2007-07-11 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting | |
| P478 | volume | 61 |
| Q99634133 | ANalogical UroFlowmetry (ANUF): correspondence between this new visual pictogram and uroflowmetry in men with lower urinary tract symptoms.: A new approach for the study of male micturition dynamics |
| Q37826454 | Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review |
| Q33744340 | Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians |
| Q39990115 | Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial |
| Q39157031 | Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients |
| Q43644314 | Clinical features of supervoiders who suffer from lower urinary tract symptoms: a propensity score-matching study |
| Q37994725 | Combination pharmacological therapies for the management of benign prostatic hyperplasia |
| Q35643437 | Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey. |
| Q57474731 | Design and methodology of the screening for CKD among older patients across Europe (SCOPE) study: a multicenter cohort observational study |
| Q41986288 | Diagnosis and management of benign prostatic hyperplasia in primary care. |
| Q53091375 | Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. |
| Q36432096 | Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions |
| Q34027912 | Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting |
| Q53219069 | Examining lower urinary tract symptom constellations using cluster analysis. |
| Q30373008 | Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. |
| Q40035548 | Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy? |
| Q35207995 | Management of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in Jakarta |
| Q57582176 | Minimally Invasive Therapies |
| Q95643048 | No Relationship Between the International Prostate Symptom Score and Post-Void Residual Volume in Primary Care |
| Q44125663 | Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic |
| Q35076391 | Overactive bladder in males |
| Q37973041 | Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes |
| Q39163861 | Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study |
| Q39024174 | Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms : An overview |
| Q42140433 | Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study |
| Q38171532 | Tadalafil - a therapeutic option in the management of BPH-LUTS. |
| Q48139585 | Tailoring pharmacotherapy for male lower urinary tract symptoms: A prospective, multicenter, observational trial. |
| Q33829176 | The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (Com |
| Q39296065 | The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. |
| Q38136528 | The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP. |
| Q27025700 | The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors |
| Q51865877 | The treatment of overactive bladder: a primary care provider's perspective. |
| Q39090324 | Treatment of Concomitant OAB and BPH. |
| Q38913916 | α-Blockers, 5-α-Reductase Inhibitors, Acetylcholine, β3 Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes? |
Search more.